AstraZeneca Completes Acquisition of Ardea Biosciences
20 Junio 2012 - 2:18AM
Noticias Dow Jones
LONDON--Biopharmaceutical business AstraZeneca PLC (AZN.LN) said
Wednesday that on June 19 it completed its acquisition of San
Diego, California-based biotechnology company Ardea Biosciences,
Inc. (RDEA).
MAIN FACTS:
-Upon completion of the merger, each outstanding share of Ardea
common stock was cancelled and converted into the right to receive
32 dollars, in cash, without interest, and shares of Ardea common
stock ceased trading on the NASDAQ Global Select Market.
-AstraZeneca shares closed Tuesday at 2760 pence valuing the
company at 34.8 billion pounds.
-Write to Ian Walker at ian.walker@dowjones.com
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Ardea Biosciences, Inc. (MM) (NASDAQ): 0 recent articles
Más de Ardea Biosciences Inc. Artículos de Noticias